Clinical and pharmacogenetic studies of iloperidone.
Antipsychotic drugs have become the mainstay treatment of schizophrenia. However, patients who receive antipsychotic treatment differ with respect to treatment response and adverse events. The problem of antipsychotic response variability has stimulated further search for agents with improved effectiveness and tolerability. Equally intense is the search for novel ways of using DNA information to personalize treatment with antipsychotic drugs. Iloperidone is an investigational, atypical antipsychotic drug of the serotonin/dopamine type. The US FDA is currently reviewing the new drug application for an oral formulation of iloperidone for the treatment of schizophrenia. Data from 35 clinical trials and approximately 3000 patients treated with iloperidone were included in the new drug application submission, as well as data from pharmacogenetic studies of iloperidone. Given the emerging role of pharmacogenetics, knowledge of genetic biomarkers of iloperidone response could lead to personalized medicine.